• Publications
  • Influence
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
TLDR
This newer evidence suggests that AFFs are stress or insufficiency fractures, and studies with radiographic review consistently report significant associations between A FFs and BP use, although the strength and magnitude of effect vary. Expand
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
  • E. Shane, D. Burr, +24 authors M. Whyte
  • Medicine, Biology
  • Journal of bone and mineral research : the…
  • 1 November 2010
TLDR
Given the relative rarity of atypical femoral fractures, the task force recommends that specific diagnostic and procedural codes be created and that an international registry be established to facilitate studies of the clinical and genetic risk factors and optimal surgical and medical management of these fractures. Expand
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
TLDR
A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures and was associated with a significant improvement in bone mineral density and bone metabolism markers. Expand
Clinician’s Guide to Prevention and Treatment of Osteoporosis
The Clinician’s Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council ofExpand
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
TLDR
It is found that PTH has a pronouned anabolic effect on the central skeleton in patients on hormone-replacement therapy, which increases total-body bone mineral, with no detrimental effects at any skeletal site. Expand
Clinician’s Guide to Prevention and Treatment of Osteoporosis
The Clinician’s Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council ofExpand
Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study *
TLDR
It is indicated that daily PTH treatment exerts anabolic action on cortical bone in patients with osteoporosis and also can improve cancellous bone microarchitecture. Expand
Anabolic actions of parathyroid hormone on bone.
TLDR
The potential for an agent that can increase bone mass and hence reverse the skeletal defect in patients with osteoporosis is great, particularly if in doing so it also repairs microarchitectural damage. Expand
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
TLDR
In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. Expand
The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)
TLDR
Small differences in bone density and markers in those who continued versus those who stopped treatment suggest residual effects, and therefore, after 3 years of annual ZOL, many patients may discontinue therapy up to 3 years, however, vertebral fracture reductions suggest that those at high fracture risk, particularly vertebral fractures, may benefit by continued treatment. Expand
...
1
2
3
4
5
...